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Abstract 
Granular corneal dystrophy (GCD) is an autosomal dominant hereditary disease 
in which multiple discrete and irregularly shaped granular opacities are 
deposited in the corneal stroma. GCD is caused by a point mutation in the 
transforming growth factor-β-induced (TGFBI) gene, located on chromosome 
5q31. Here, we report the first successful application of CRISPR-Cas9-mediated 
genome editing for the correction of a TGFBI mutation in GCD patient-derived 
primary corneal keratocytes via homology-directed repair (HDR). To correct 
genetic defects in GCD patient cells, we designed a disease-specific guide RNA 
(gRNA) targeting the R124H mutation of TGFBI, which causes GCD type 2 
(GCD2, Avellino corneal dystrophy). An R124H mutation in primary human 
corneal keratocytes derived from a GCD2 patient was corrected by delivering a 
CRISPR plasmid expressing Cas9/gRNA and a single-stranded 
oligodeoxynucleotide HDR donor template in vitro. The gene correction 
efficiency was 20.6% in heterozygous cells and 41.3% in homozygous cells. No 
off-target effects were detected. These results reveal a new therapeutic strategy 
for GCD2; this method may also be applicable to other heredity corneal 
diseases. 
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Introduction 1 
Granular corneal dystrophy (GCD) is a bilateral, progressive, genetic, and 2 
non-inflammatory disease characterised by multiple granular deposits in the corneal stroma. 3 
Using the IC3D classification1, GCD has three subtypes, all of which are classified as 4 
Category 1, i.e., causal point mutations have been identified in the transforming growth 5 
factor-beta-induced (TGFBI) gene, located on chromosome 5q312. TGFBI, also called 6 
keratoepithelin or Big-h3, is 68-kDa protein found in the extracellular matrix of human tissues. 7 
It is particularly abundant in the cornea.  8 
There are two clinical types of GCD, GCD1 and GCD2. Although originally described 9 
in a family from the Italian region of Avellino, the R124H mutation associated with GCD2 is 10 
occurs in unrelated individuals in all populations studied and is the most common type in 11 
Asia, including Japan3,4. In GCD2, discrete grey-white granular deposits (hyaline) with 12 
snowflake, star, or disk shapes are detected in the corneal stroma at an early age5 and 13 
amyloid deposits are observed in elder patients in deeper stroma6. GCD2 has a diffuse 14 
anterior stromal haze between the typical granular opacity. The haze may be caused by 15 
amyloid deposits, which are thought to be similar to Gelatinous drop-like CD, instead of the 16 
linear opacity seen in the early stage of lattice dystrophy6,7. Compared to heterozygous 17 
patients, homozygous patients may have an onset under 10 years old, and demonstrate a 18 
more rapid progression. These progressive corneal opacities cause a loss of visual acuity. 19 
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To avoid visual impairment in GCD2, phototherapeutic keratectomy (PTK) is a major 20 
treatment option. However, multiple opacities usually recur within several years8. Compared 21 
with PTK, corneal clarity can be retained for longer durations using keratoplasty, but opacity 22 
eventually occurs via the gradual invasion of host corneal cells, especially in homozygous 23 
patients9. Thus, the development of a radical treatment is needed. GCD2 is typically 24 
associated with an R124H (histidine replacing arginine) point mutation in the TGFBI gene; 25 
accordingly, a gene therapy approach may be effective.  26 
      CRISPR/Cas9 (clustered, regularly interspaced short palindromic repeats 27 
(CRISPR)/CRISPR-associated protein)-mediated genome editing has been increasingly 28 
applied to repair mutated genome sequences10. This versatile tool for genome engineering 29 
enables the induction of site-specific double-strand breaks (DSBs) using guide RNAs 30 
(gRNAs)11-15 . DSBs can be repaired by two major pathways, non-homologous end joining 31 
and homology-directed repair (HDR). In the presence of exogenous donor DNA as a repair 32 
template, DSBs can be repaired precisely via the HDR pathway. This technique is useful for 33 
codon replacements or reporter insertions16,17. For small genetic modifications, such as point 34 
mutations, the application of single-stranded oligodeoxynucleotides (ssODNs) as HDR 35 
templates shows higher editing efficiency than that of plasmid donors18. Here, we report the 36 
first CRISPR-mediated HDR using cultured corneal keratocytes derived from an R124H 37 
GCD2 patient. The results of this study have important clinical implications given the lack of 38 
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effective treatment options for GCD2. 39 
 40 
Results 41 
Gene targeting strategy and construction for CRISPR/Cas9-mediated HDR of an R124H 42 
mutation 43 
        To develop an efficient strategy to repair the genetic mutation in GCD using 44 
CRISPR/Cas9, we used human cultured corneal keratocytes derived from an R124H GCD2 45 
patient as a model system. The TGFBI R124H mutant keratocytes have a monoallelic point 46 
mutation at Arg124 (GCAàACA) in Exon 4 of TGFBI (Figure 1a). To repair mutant R124H 47 
cells, we designed an R124H mutation-specific gRNA based on a public algorithm (Figure 48 
1b). Then, the designed gRNAs were computationally evaluated for potential off-target 49 
effects using the E-CRISP algorithm. The gRNA with the lowest off-target risk was selected 50 
for subsequent analyses.  51 
For the HDR repair template, we synthesized a 100-nucleotide (nt) donor repair template 52 
ssODN with a novel BsiWI restriction site (Figure 1b). The substitutions ensured that the 53 
sequence of the wild-type donor template was resistant to CRISPR/Cas9 cleavage by the 54 
R124H mutation-specific gRNA, and the BsiWI restriction site allowed the tracking of HDR 55 
by restriction fragment length polymorphism (RFLP) (Figure 1b). A pair of annealed oligos 56 
encoding a target sequence of R124H mutation-specific gRNA was cloned into the px458 57 
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vector, which enabled bicistronic expression of Streptococcus pyogenes Cas9 (spCas9) and 58 
green fluorescence protein (GFP) (Figure 1c).   59 
 60 
CRISPR/Cas9-mediated HDR of an R124H mutation in human corneal keratinocytes 61 
The CRISPR plasmid expressing spCas9/gRNA was co-transfected into primary R124H 62 
mutant human corneal keratinocytes with the ssODN as a donor template. After 7 days, 63 
single GFP-expressing cells were harvested, added to individual wells of a 96-well plate, and 64 
clonally expanded. Then, the presence of a novel BsiWI restriction site was examined by 65 
RFLP-based genotyping. Genomic PCR products for wild-type alleles were not cleaved by 66 
BsiWI (Figure 2a). However, genomic PCR products for several transfected colonies were 67 
cleaved by BsiWI, suggesting target site alterations by HDR (Figure 2a). We also confirmed 68 
the genomic sequences of the PCR products (Figure 2b).   69 
      The sequence of wild-type cells had CGC, specifying arginine, at the 124th amino acid, 70 
and R124H mutant cells had CAC at this position. Neither is expected to be cleaved by 71 
BsiWI; however, gene-edited cells have CGT, which is expected to be cut at CGTAC. In an 72 
RFLP assay, we detected cells with heterozygous and homozygous editing, as shown in 73 
Figure 2c.  74 
 75 
Efficiency of Cas9-mediated genome editing of the TGFBI R124H mutant gene  76 
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           To examine the editing efficiency of the R124H mutant TGFBI gene, genomic 77 
DNA was extracted from the clonally expanded cells in 96-well plates and examined by 78 
RFLP-based genotyping. Owing to the low growth rate and viability of flow cytometry-sorted 79 
primary keratinocytes, not all cells were sufficiently expanded by single-cell cloning in 80 
96-well plates. Cell growth and gene editing efficiency are summarised in Figure 2c. 81 
Thirty-eight out of 192 clones were sufficiently expanded and examined by RFLP. Among all 82 
examined clones, 20.6% exhibited monoallelic TGFBI correction and 41.3% showed biallelic 83 
correction. Accordingly, 62% showed clear TGFBI R124H allele correction derived from the 84 
HDR template. 85 
 86 
Analysis of off-target cleavage by R124H mutation-specific gRNA 87 
 To evaluate off-target effects mediated by the gRNA, a T7 endonuclease (T7EN1) 88 
cleavage assay was used to assess off-target cleavage. Since we rigorously designed and 89 
selected a TGFBI-specific gRNA to reduce the risk of off-target effects, only 3 potential 90 
off-target sites were found for the gRNA (Figure 3a, 3b). We could not find any potential 91 
off-target sites (OTS) with mismatches of less than 3 nt. The 3 potential OTS had 92 
mismatches of more than 4 nt with the TGFBI gRNA (Figure 3b). In the T7EN1 cleavage 93 
assay, we did not detect any off-target effects at the 3 OTS (Figure 3c).  94 
 95 
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Discussion  96 
Current therapeutic modalities for GCD, i.e. PTK and keratoplasty, are invasive and are 97 
associated with frequent recurrence. The correction of TGFBI mutations in the local cornea 98 
may be a radical treatment for GCD patients, minimizing progression and the recurrence of 99 
corneal opacities. In this study, we successfully repaired point mutations in R124H mutant 100 
cells using CRISPR/Cas9 and HDR in vitro, without detectable off-target effects. 101 
The CRISPR/Cas 9 system is an efficient tool for genome engineering and disease 102 
treatment. Kaminski et al. successfully eliminated HIV genomes in human T cells ex vivo19; 103 
they reported a low editing efficiency in primary culture, even using a lentivirus delivery 104 
system19. Similarly, the low transfection and growth efficiency in this study (Figure 2c) may 105 
be attributed to the use of primary culture cells. However, in general, plasmid transfection 106 
may be safer than viral transfection in vivo. Fortunately, despite the low growth rate, our 107 
results reveal that the efficiency of CRISPR/Cas9 in gene correction was higher compared 108 
with those of previous studies15. It is reported that the efficacy of HDR is generally not high, 109 
however, the efficiency of HDR using asymmetric donor DNA is much higher (maximum 110 
60%) than that of conventional HDR20. In this study, the efficacy of HDR using ssODN was 111 
greater than 60%. The reason for the high efficiency of HDR in our study is unclear, but may 112 
be explained by the unique characteristics of the DNA repair ability of corneal epithelial cells. 113 
Previously, Mallet et al.21 demonstrated that DNA damage in human corneal epithelial cells 114 
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by ultraviolet radiation could be repaired faster than that in epidermal keratinocytes. This 115 
suggests that there are corneal-specific mechanisms in DSB repair. This issue should be 116 
evaluated in future studies.  117 
CRISPR/Cas9 itself has some probability of causing off-target mutations22,23. 118 
CRISPR RNA-guide endonucleases tolerate single and double mismatches in their 119 
sequences at the gRNA interface in bacterial cells22 and human cells23. Wu et al.24 reported 120 
that only 2 out of 12 samples had off-target mutations when they co-injected Cas9 mRNA 121 
and a single gRNA into mouse zygotes with dominant mutations in Crygc that cause 122 
cataracts. Additionally, off-target mutations were detected at 1 of 10 potential OTS in the two 123 
samples. Thus, although off-target effects are an important safety issue for clinical use, they 124 
can be greatly reduced by a cautious gRNA sequence design25,26. Moreover, according to 125 
previous studies, gRNA does not cleave nonspecific targets with mismatches of 3 nt or 126 
more23,27. In our study, based on these findings, we made highly specific gRNAs using an 127 
off-target prediction tool. A T7 Endonuclease 1 cleavage assay was performed to examine 128 
off-targets effects, but the three predicted OTS were not detected in any sample (Figure 3c).  129 
In ocular tissues, several reports have demonstrated successful gene editing using 130 
the CRISPR/Cas9 system28-31. Wu et al. corrected a genetic disease in mice that show 131 
early-onset cataracts using non-homologous end joining and HDR24. The gene correction 132 
was conducted at the embryonic stage and cataracts occurred in 10 out of 12 mice. Wang et 133 
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al.32 and Bakondi et al.30 successfully edited retinal genes by electroporation, and Hung et 134 
al.28 also successfully edited retinal genes using a virus delivery system. In the cornea, 135 
Courtney et al. reported the effectiveness of DNA cleavage by CRISPR/Cas9 for the 136 
treatment of cornea dystrophy caused by a KRT12 mutation29. To our knowledge, this study 137 
is the first to demonstrate in vitro gene correction in mutant human primary corneal cells 138 
using CRISPR/Cas9 and HDR. The cornea is an excellent tissue for the application of 139 
genome editing therapy owing to its accessibility and high amenability to naked plasmid 140 
DNA transfection via intrastromal injection33. Thus, gene editing is a radical GCD treatment 141 
and the in vivo application of this system is ideal for clinical settings in which conventional 142 
treatments are limited. In the future, it is necessary to develop safer and more efficient 143 
methods to modify local corneal genes in vivo.  144 
In conclusion, we used CRISPR-Cas9-mediated HDR to correct the R124H mutation. 145 
Our data suggest that the approach is highly specific, with no observed off-target effects. 146 
Given the lack of effective treatment options for GCD2, this gene editing system is a 147 
potentially radical treatment for TGFBI-related corneal dystrophy and can be used to protect 148 
corneal opacities. The in vivo application of this system is an important future challenge.   149 
 150 
 151 
Methods 152 
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Cell culture 153 
Primary human corneal keratocytes of a GCD2 patient with a heterozygous TGFBI 154 
mutation (R124H) were isolated from a surgical specimen during deep anterior lamellar 155 
keratoplasty. Ethics approval for this work was obtained from the Institutional Review Board 156 
of the Inoue Eye Hospital and informed consent was obtained from the patient. All tissues 157 
were provided form Inoue Eye Hospital and no tissues were procured from prisoners. All the 158 
experimental methods were carried out in accordance with the guidelines verified and 159 
approved by the Ethics Committee of The University of Tokyo. 160 
The cell culture method was described previously34-36. Briefly, the corneal epithelium 161 
was removed from the stroma of the surgical specimen by scraping with a razor blade. A 162 
stromal button was incubated overnight at 37°C in basal medium, i.e. DMEM/F12 medium 163 
supplemented with B27 (Invitrogen, Carlsbad, CA, USA) containing 0.02% collagenase 164 
(Sigma-Aldrich, St. Louis, MO, USA). Subsequently, the digested tissue and cells were 165 
dispersed by pipetting and centrifuged at 800 × g for 5 min. After removing the supernatant, 166 
the keratocytes were resuspended in 1.0 mL of basal culture medium and seeded in culture 167 
dishes. The medium was changed every 2 days until the cells reached confluence. 168 
Second-passage cells were used in the subsequent transfection and other assays.  169 
 170 
gRNA design and CRISPR-Cas9 construct 171 
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         Single gRNA targeting the R124H mutation site of the human TGFBI gene was 172 
designed using the CRIPSR design tool (publically available at http://crispr.mit.edu/, 173 
http://www.e-crisp.org/E-CRISP/). To construct the CRISPR-Cas9 plasmid targeting the 174 
human TGFBI gene, the complementary oligonucleotides hTGFBI gRNA-F and hTGFBI 175 
gRNA-R were phosphorylated using T4PNK (TAKARA, Kusatsu, Japan), annealed, and 176 
cloned into pSpCas9 BB-2A-GFP (PX458, plasmid #48138; Addgene, Cambridge, MA, 177 
USA) via the BbsI restriction sites. To utilize HDR to edit the human TGFBI R124H mutation, 178 
a 100-nt ssODN (hTGFBI R124H HDR ssODN) was designed to target the R124H mutation 179 
site. 180 
The oligonucleotide sequences were as follows: 181 
 hTGFBI gRNA-F: 5′-CACCACTCAGCTGTACACGGACCACA -3′,  182 
hTGFBI gRNA-R: 5′-AAACTGTGGTCCGTGTACAGCTGAGT-3′,  183 
and hTGFBI R124H HDR ssDNA: 184 
5′-GAGACCCTGGGAGTCGTTGGATCCACCACCACTCAGCTGTACACGGACCGTACGG185 
AGAAGCTGAGGCCTGAGATGGAGGGGCCCGGCAGCTTCACCATCT-3′. 186 
 187 
Transfection and cloning 188 
         CRISPR-Cas9 constructs (2.5 µg per well) and ssODN (1 µg per well) were 189 
transfected into R124H primary cells using FuGENE (Promega, Madison, WI, USA) 190 
13 
 
according to the manufacturer’s instructions and the cells were incubated for an additional 191 
48 h. Images were obtained by fluorescence microscopy (BZ-9000; Keyence, Osaka, Japan). 192 
The cells expressing GFP were single-cell-sorted by FACS (Aria III, Becton-Dickinson, 193 
Franklin Lakes, NJ, USA) at 1 week after transfection. The sorted cells were then clonally 194 
expanded and analysed as described below.  195 
 196 
Indel analysis by restriction fragment length polymorphism (RFLP) 197 
         Total DNA was extracted from cells using the Nucleospin Kit (Takara Bio Inc.). 198 
Polymerase chain reaction (PCR) using specific primer sets (Forward: 199 
5′-GTTGAGTTCACGTAGACAGGC-3′, Reverse: 5′-GACTCCCATTCATCATGCCCA-3’) 200 
was performed to amplify the DNA using the KOD FX Kit (KOD FX; Toyobo, Osaka, Japan) 201 
with the following temperature profile: 94°C for 2 min, followed by 40 cycles of 98°C for 10 s 202 
and 55°C for 30 s, and 72°C for 2 min. The PCR products were treated with the restriction 203 
enzyme BsiWI (New England Biolabs, Ipswich, MA, USA). One microgram of DNA was 204 
treated with 1 unit of enzyme and NE Buffer 2.1 at 55°C for 15 min. The samples were 205 
analysed by electrophoresis on a 5% polyacrylamide TBE gel. 206 
 207 
DNA sequencing analysis 208 
The target site (exon 4 of TGFBI) was amplified by PCR with primers (Forward: 209 
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5′-GTTGAGTTCACGTAGACAGGC-3′, Reverse: 5′-GACTCCCATTCATCATGCCCA-3’) 210 
targeting the genomic DNA of R124H-edited cells. After the purification of PCR products, the 211 
sequence of samples was analysed using a contract genome sequencing service. 212 
(Eurofins Genomics Inc., Tokyo, Japan).  213 
 214 
T7 Endonuclease I cleavage assay 215 
        The genome editing efficiency was investigated using a T7 endonuclease I 216 
cleavage assay. Genomic regions surrounding the target sites and potential off-target sites 217 
of gRNAs were amplified by PCR using Takara ExTaq (Takara Bio Inc.). Two hundred 218 
nanograms of gel-purified PCR products was re-suspended in NEB Buffer 2, and a 219 
hybridization reaction was performed using a thermocycler (BioRad, Hercules, CA, USA) 220 
with the following settings: 95°C	 for 5 s, 95–85°C at −2°C/s, 85°C for 30 s, 85–25°C at 221 
−0.1°C/s, 25°C for 30 s, followed by maintenance at 4°C. Five units of T7 endonuclease I 222 
(New England Biolabs) were added to digest the re-annealed DNA. After 2 h of incubation at 223 
37°C, DNA products were loaded on a 2% agarose gel and visualised after staining with 224 
ethidium bromide. Primers are listed in Table 1. 225 
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Figure Legends 325 
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Figure 1 327 
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Gene targeting strategy for CRISPR/Cas9-mediated HDR of a TGFBI R124H mutation. 328 
(a) Schematic diagram of the TGFBI mutation in GCD2 in humans. (b) In GCD2, the 124th 329 
protein position is histidine (H), instead of arginine (R). The recognition sight of donor 330 
single-strand DNA is also shown. (c) Linear structure of the plasmid transfected into R124H 331 
mutant cells. The plasmid (px 458) includes guide RNA targeting R124H mutant cells, Cas 9 332 
protein sequences, and EGFP. TGFBI, transforming growth factor β-induced; GCD2, 333 
granular corneal dystrophy; HDR, homology-directed repair.  334 
 335 
Figure 2  336 
Correction of the mutation in TGFBI R124H mutant keratocytes using 337 
CRISPR-mediated HDR. 338 
(a) Result of an RFLP analysis of edited R124H cells. TGFBI exon 4 was amplified by PCR, 339 
and the products were treated with the BsiWI restriction enzyme. The lane with three bands 340 
was edited heterozygously and the lane with two bands was edited homozygously. (b) DNA 341 
sequences of PCR products amplified from the TGFBI gene of wild-type cells, a 342 
heterogeneous R124H mutant, and a repaired allele by HDR after transfection of Cas9 guide 343 
RNA and ssDNA. Two peaks were observed in the sequence of the R124H heterogeneous 344 
mutant, while the base of HDR-repaired cells was corrected to T. (c) Editing efficiency of 345 
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CRISPR/Cas9-mediated HDR of an R124H mutation. RFLP, restriction fragment length 346 
polymorphism TGFBI, transforming growth factor β-induced; HDR, homology-directed 347 
repair. 348 
 349 
Figure 3  350 
Off-target sites and T7 endonuclease cleavage assay of potential off-target loci. 351 
(a) Ranked list of potential off-target loci for R124H mutation-specific gRNA. Number of 352 
mismatched bases, PAM sequence, chromosomes, and target gene are indicated. (b) 353 
Sequence alignments of R124H mutation-specific gRNA and potential off-target loci. (c) 354 
Potential off-target sites in edited cells were amplified by PCR. After T7 endonuclease 355 
treatment, no off-targets effects were found at any site. 356 
N/A: not applicable 357 
 358 
Table 1 Primer set used for the T7 endonuclease cleavage assay of potential 359 
off-target loci. 360 
 361 
 362 
Column1 Forward Reverse 
#1 5′-ATGTCAGAAGTCCCGCTGTG-3′ 5′–TGATGGGGTCAGAGGGCATA–3′ 
#2 5′-GCAGCAAAGCACTCAAGAGG-3′ 5′-CAAACTTCTGCCTGGGCATC-3′ 
#3 5′-CTTCCTGCTCTGTGTTTAGCCA-3′ 5′-ACCTCCAAGTTGAGCAGTGTC -3′ 
20 
 
 363 
1 Weiss, J. S. et al. IC3D classification of corneal dystrophies--edition 2. Cornea 34, 117-159, (2015). 364 
2 Munier, F. L. et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet 365 
15, 247-251, (1997). 366 
3 Mashima, Y. et al. Association of autosomal dominantly inherited corneal dystrophies with 367 
BIGH3 gene mutations in Japan. Am J Ophthalmol 130, 516-517, (2000). 368 
4 Kim, H. S., Yoon, S. K., Cho, B. J., Kim, E. K. & Joo, C. K. BIGH3 gene mutations and rapid 369 
detection in Korean patients with corneal dystrophy. Cornea 20, 844-849, (2001). 370 
5 Akiya, S., Takahashi, H., Nakano, N., Hirose, N. & Tokuda, Y. Granular-lattice (Avellino) corneal 371 
dystrophy. Ophthalmologica 213, 58-62, (1999). 372 
6 Folberg, R. et al. Clinically atypical granular corneal dystrophy with pathologic features of 373 
lattice-like amyloid deposits. A study of these families. Ophthalmology 95, 46-51, (1988). 374 
7 Dubord, P. J. & Krachmer, J. H. Diagnosis of early lattice corneal dystrophy. Arch Ophthalmol 375 
100, 788-790, (1982). 376 
8 Dinh, R., Rapuano, C. J., Cohen, E. J. & Laibson, P. R. Recurrence of corneal dystrophy after 377 
excimer laser phototherapeutic keratectomy. Ophthalmology 106, 1490-1497, (1999). 378 
9 Stuart, J. C. et al. Recurrent granular corneal dystrophy. Am J Ophthalmol 79, 18-24, (1975). 379 
10 Makarova, K. S. et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 380 
9, 467-477, (2011). 381 
11 Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome 382 
engineering. Cell 157, 1262-1278, (2014). 383 
12 Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with the 384 
Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232, (2013). 385 
13 Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823, 386 
(2013). 387 
14 Jinek, M. et al. RNA-programmed genome editing in human cells. Elife 2, e00471, (2013). 388 
15 Mali, P. et al. RNA-Guided Human Genome Engineering via Cas9. Science 339, 823-826, (2013). 389 
16 San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous recombination. Annu 390 
Rev Biochem 77, 229-257, (2008). 391 
17 Liang, F., Han, M., Romanienko, P. J. & Jasin, M. Homology-directed repair is a major 392 
double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci U S A 95, 5172-5177, 393 
(1998). 394 
18 Wiles, M. V., Qin, W., Cheng, A. W. & Wang, H. CRISPR-Cas9-mediated genome editing and 395 
guide RNA design. Mamm Genome 26, 501-510, (2015). 396 
19 Kaminski, R. et al. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by 397 
CRISPR/Cas9 Gene Editing. Sci Rep 6, 22555, (2016). 398 
20 Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing 399 
homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using 400 
21 
 
asymmetric donor DNA. Nat Biotechnol 34, 339-344, (2016). 401 
21 Mallet, J. D. et al. Faster DNA Repair of Ultraviolet-Induced Cyclobutane Pyrimidine Dimers and 402 
Lower Sensitivity to Apoptosis in Human Corneal Epithelial Cells than in Epidermal 403 
Keratinocytes. PLoS One 11, e0162212, (2016). 404 
22 Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided editing of bacterial 405 
genomes using CRISPR-Cas systems. Nat Biotechnol 31, 233-239, (2013). 406 
23 Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human 407 
cells. Nat Biotechnol 31, 822-826, (2013). 408 
24 Wu, Y. et al. Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9. Cell Stem Cell 13, 409 
659-662, (2013). 410 
25 Yang, H. et al. One-step generation of mice carrying reporter and conditional alleles by 411 
CRISPR/Cas-mediated genome engineering. Cell 154, 1370-1379, (2013). 412 
26 Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat 413 
Biotechnol 31, 681-683, (2013). 414 
27 Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases 415 
and nickases. Genome Research 24, 132-141, (2013). 416 
28 Hung, S. S. et al. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo. Invest 417 
Ophthalmol Vis Sci 57, 3470-3476, (2016). 418 
29 Courtney, D. G. et al. CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and 419 
in vivo KRT12 mutation-specific targeting. Gene Therapy 23, 108-112, (2015). 420 
30 Bakondi, B. et al. In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the 421 
S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa. Molecular Therapy 24, 422 
556-563, (2015). 423 
31 Wu, W.-H. et al. CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis 424 
Pigmentosa. Molecular Therapy 24, 1388-1394, (2016). 425 
32 Wang, S., Sengel, C., Emerson, M. M. & Cepko, C. L. A gene regulatory network controls the 426 
binary fate decision of rod and bipolar cells in the vertebrate retina. Dev Cell 30, 513-527, (2014). 427 
33 Stechschulte, S. U. et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest 428 
Ophthalmol Vis Sci 42, 1975-1979, (2001). 429 
34 Yamagami, S. et al. Distribution of Precursors in Human Corneal Stromal Cells and Endothelial 430 
Cells. Ophthalmology 114, 433-439, (2007). 431 
35 Sakai, R. et al. Construction of human corneal endothelial cDNA library and identification of 432 
novel active genes. Invest Ophthalmol Vis Sci 43, 1749-1756, (2002). 433 
36 Toyono, T. et al. Angiopoietin-like 7 is an anti-angiogenic protein required to prevent 434 
vascularization of the cornea. PLoS One 10, e0116838, (2015). 435 
 436 
